One study examined the efficacy of a metabolic inhibitor cocktail containing transforming growth factor beta-activated kinase 1 (TAK1) (AMPK activator) and FASN synthase inhibitors against ovarian cancer cells [97]. The gene discussed is MAP3K7; the disease is ovarian cancer.